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Abstract
Background: The association between mortality and localization of central thrombus in hemodynami-
cally stable patients with pulmonary embolism (PE) is unclear. Sufficient data are not available to help 
clinicians to select between low molecular weight heparin (LMWH), unfractionated heparin (UFH) and 
thrombolytics for the management of central thrombus. The present study aims to investigate whether 
central thrombus in the pulmonary artery affects 30-day mortality rate, and to compare the outcomes of 
different treatment approaches in patients with central thrombus. 
Methods: This multi-central, prospective, observational study included 874 hemodynamically stable 
patients with PE confirmed by multidetector computed tomography scan. The localization of the emboli 
was evaluated and categorized as central (saddle or at least one main pulmonary artery), lobar or distal. 
The primary study outcome was 30-day all-cause mortality.
Results: Localization of the emboli was central in 319 (36.5%) patients, lobar in 264 (30.2%) and 
distal in 291 (33.2%) patients. Seventy-four (8.5%) patients died during the 30-day follow-up period. 
All-cause mortality rate was 11.9%, 6.8% and 6.2% in patients with central, lobar, and distal em-
boli, respectively (p < 0.001). Multivariate analysis did not show that hemodynamically stable central 
thrombus was an independent predictor of mortality. Additionally, mortality rate was not significantly 
different between UFH, LMWH and thrombolytic therapy groups. 
Conclusions: The present study showed that central thrombus was not an independent predictor of 
mortality in hemodynamically stable PE patients. LMWH and UFH were similarly effective in the treat-
ment of this patient group. (Cardiol J 2017; 24, 5: 508–514)
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Introduction
The clinical signs of pulmonary embolism 
(PE) vary from silent or very mild symptoms to 
massive findings that result in sudden death [1]. 
Previous reports showed that the level of vascular 
occlusion, number, size and location of the emboli, 
and patient’s age and comorbidities are the most 
important determinants of the severity of patient 
signs and symptoms. Defining the appropriate 
treatment protocols based on risk stratification is 
essential in preventing complications in patients 
with suspected PE [2]. On the other hand, delays 
in diagnosis or inaccurate risk stratification may 
result in serious morbidity and mortality. 
A prompt and efficient risk stratification of 
patients is crucial in PE treatment. Although echo-
cardiography and cardiac biomarkers play important 
roles in diagnosis and risk stratification based on 
clinical history of normotensive PE patients, many 
of these markers still do not have large clinical 
availability and clinicians continue to seek more 
accurate means of risk stratification [2]. Recent 
advances in multi-detector computed tomography 
(MDCT) have significantly improved our ability to 
diagnose fatal PE.
Since mortality rate is high among patients 
with massive embolism and unstable hemodynamic 
findings, it is indisputable that these patients must 
be provided with rapid and aggressive treatment. 
However, mortality rate in normotensive patients 
with central thrombosis is unclear and sufficient 
data are not available to help the clinicians to select 
between different treatment options, such as with 
low molecular weight heparin (LMWH), unfraction-
ated heparin (UFH) and thrombolytics [3].
The present study aims to investigate whether 
central thrombus in the pulmonary artery affects 
30-day mortality rate, and to compare the outcomes 
of different treatment approaches in patients with 
central thrombus.
Methods
Study design
This study was conducted between January 
2013 and June 2013, as part of a large prospective 
multi-center study carried out in 66 study centres 
in Turkey. Data prospectively collected from pa-
tients enrolled to the Turkey Pulmonary Embolism 
Groups (TUPEG) were assessed in this study [4]. 
The study population consisted of 874 patients with 
PE diagnosed by MDCT scan. Written informed 
consent was obtained from all patients and the 
study protocol was approved by the local ethics 
committee of the coordinating centre (Approval 
Number: 173/2012). 
Patients and setting
The study population consisted of 874 patients 
who were admitted with normotensive acute PE. 
Demographic characteristics, clinical and labora-
tory data of all patients were obtained from the 
electronic databases of the participating hospitals. 
Well score for PE was calculated for each patient. 
Laboratory parameters (D-dimer, high sensitive 
troponin-I or troponin-T, natriuretic peptides) 
were analysed according to local standards. The 
recorded comorbidities included history of venous 
thromboembolism (VTE), malignancy, chronic 
obstructive pulmonary disease (COPD), coronary 
artery disease, cerebrovascular disease and con-
gestive heart failure. 
Severity of pulmonary embolism was classified 
in three groups according to the European Society 
of Cardiology guidelines as follows: high-risk (pa-
tients with shock or hypotension); intermediate-
risk (presence of a positive marker for myocardial 
injury or right ventricular dysfunction [RVD]); 
low-risk (absence of RVD or negative marker of 
myocardial injury) [5]. PE patients with shock 
or hypotension (high risk defined by the ESC as 
systolic blood pressure of 90 mm Hg or a pressure 
drop of ≥ 40 mm Hg for 15 min if not caused by new 
onset arrhythmia) were excluded from the study. 
MDCT scan was performed in all patients and 
assessed for localization of the thrombus. Throm-
bus localization was evaluated and categorized 
as follows: central (saddle or at least one main 
pulmonary artery), lobar and distal (segmental or 
subsegmental pulmonary arteries). 
Study outcome
The primary study outcome was 30-day all-
cause death or clinical deterioration in hemody-
namically stable patients with central thrombus. 
The secondary outcomes included all-cause mortal-
ity, non-fatal symptomatic re-embolism VTE, and 
non-fatal major haemorrhage.
Statistical analyses
Statistical analyses were performed with the 
SPSS for Windows version 17.0 (SPSS Inc., Chi-
cago, IL, USA). The Kolmogorov-Smirnov test was 
applied to determine probability distribution. Data 
were reported as percentages, means ± standard 
deviations (SD) and medians, where appropriate. 
Kruskal Wallis test was used for inter-group com-
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parisons and discrete variables were compared by 
the c2 test. P values < 0.05 were considered sta-
tistically significant in all analyses. All factors with 
potential effects on 30-day mortality were further 
investigated by univariable screening. Subsequently, 
all parameters found to be associated with 30-day 
mortality at a significance level lower than 0.1 were 
analyzed in a stepwise multivariable Cox regression 
analysis. Results were reported as odds ratios (ORs) 
and 95% confidence intervals (CIs).
Results
A total number of 1214 patients with acute PE 
were evaluated. Of these, 340 (27%) were excluded 
because MDCT-scanning was not performed or 
because the patients were not available for echo-
cardiography and/or troponin measurements and 
121 patients were excluded because they were not 
hemodynamically stable (Fig. 1). 
The median age at diagnosis was 67 ± 16.8 
years (range 19–96 years), and 350 (46.5%) pa-
tients were male. Localization of emboli was cen-
tral in 319 (36.5%) patients, lobar in 264 (30.2%) 
and distal in 291 (33.2%) patients. There was no 
correlation between localization of emboli and sex 
or age. In terms of comorbidities, 79 (9%) patients 
had cardiopulmonary disease, 54 (6.2%) had COPD, 
62 (7%) had congestive heart failure, 36 (4.1%) had 
history of ischemic stroke, and 88 (10.1%) patients 
had history of cancer.
The most common symptom at presenta-
tion was dyspnoea (85%), followed by chest pain 
(47%), haemoptysis (12%) and syncope (6%). 
No risk factor was recorded in 173 (20%) cases. 
Patient characteristics are shown in Table 1. 
Univariate analysis showed that RVD on echo-
cardiography (OR: 2.57, 95% CI: 1.85–3.48, 
p < 0.001) as well as elevated serum troponin 
levels (OR: 1.92, 95% CI: 1.43–2.60, p < 0.001) 
were independent predictors of mortality. Troponin 
concentration was found to be related to the loca-
tion of the largest visible embolus (p < 0.001); the 
highest concentrations were measured in patients 
with central thrombus and the lowest concentra-
tions were detected in the lobar-distal group. El-
evated troponin levels at presentation were more 
common in patients with RVD (p < 0.001) as well 
as central thrombi on MDCT scan (Table 2). 
Syncope was present in 29 (54%) patients with 
central, 13 (24%) patients with lobar and 12 (22%) 
patients with distal emboli. Univariate analysis 
evaluating the presence of syncope with respect 
Table 1. Characteristic features of patients  
included in the study.
 Number of patients (%)
Demographic features
Sex: females/males  
(% female)
468/406 (53.5%)
Median age [years] 67 (19–96)
Median SBP [mm Hg] 120 (90–210)
Median SaO2 [%] 92 (69–99)
Risk factors
Immobilization 236 (27.0%)
Recent surgery 114 (13.0%)
Cancer 88 (10.0%)
Idiopathic 176 (20.0%)
Symptoms at presentation
Dyspnea 745 (85.2%)
Chest pain 413 (47.3%)
Hemoptysis 106 (12.1%)
Syncope 54 (6.2%)
Localization of thrombus
Central 319 (36.5%)
Lobar 264 (30.2%)
Distal 291 (33.2%)
Co-morbid disease
Cardiopulmonary disease 79 (9.0%)
COPD 54 (6.2%)
Congestive heart failure 62 (7.0%)
Ischemic stroke 36 (4.1%)
Cancer 88 (10.1%)
COPD — chronic obstructive pulmonary disease; SBP — systolic 
blood pressure, SaO2 — oxygen saturation of arterial blood
Figure 1. Patient study eligibility; PE — pulmonary em-
bolism; sPESI — simplified pulmonary embolism index.
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to thrombus localization demonstrated that syn-
cope was statistically significantly twice as often 
among patients with central thrombus (OR 2.15, 
95% CI: 1.23–3.74, p < 0.007). Conversely, there 
was no relation between lobar (OR 0.69, 95% CI: 
0.36–1.32, p > 0.05) or distal (OR: 0.56, 95% CI: 
0.29–1.08, p > 0.05) localization of thrombi and 
presence of syncope. 
Seventy-four (8.5%) patients died during the 
30-day follow-up period. The rate of all-cause 
mortality was 11.9%, 6.8% and 6.2% in patients 
with central, lobar, and distal emboli, respectively. 
The 30-day mortality rate was higher among pa-
tients with central thrombus, compared to those 
with lobar or distal thrombus (p < 0.001) (Fig. 2). 
Although Cox analysis showed that the presence 
of thrombus in the main pulmonary artery signifi-
cantly increased the mortality rate (OR: 2.0. 95% 
CI: 1.2–3.3, p = 0.007), multivariate Cox analysis 
did not show statistical significance (Table 3). 
Among patients with central thrombus, 86 
(27%) were given UFH, 198 (62.1%) were given 
LMWH and 34 (10.7%) were administered tissue 
plasminogen activator therapy. 
Mortality rates of patients with thrombus in 
the main pulmonary artery did not significantly dif-
fer between the heparin (OR: 1.7, 95% CI: 0.8–3.6, 
p > 0.05) and LMWH (OR: 0.9, 95% CI: 0.4–1.9, 
p > 0.05) treatment groups. Use of thrombolytic 
agents also did not decrease the mortality rate in 
this patient group (Table 4). 
Among PE patients with central thrombus, 
the number of patients with high risk simplified 
pulmonary embolism index (sPESI) was higher 
than those with low risk sPESI (26.5% and 41.3%, 
respectively) (Table 5).
Table 2. Medical conditions and symptoms at presentation and according to the localization of thrombus.
Central (n = 319) Lobar (n = 264) Distal (n = 291)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Respiratory rate [min] 1.03 (1.00–1.05) 0.015 0.98 (0.95–1.00) 0.13 0.98 (0.96–1.01) 0.28
Pulse [min] 1.01 (1.00–1.01) 0.003 0.99 (0.98–1.00) 0.19 0.99 (0.98–1.00) 0.67
RVD 2.57 (1.85–3.48) 0.000 1.05 (0.77–1.42) 0.74 0.35 (0.26–0.48) < 0.0001
Elevated troponin levels 1.92 (1.43–2.60) < 0.0001 0.78 (0.57–1.08) 0.14 0.60 (0.44–0.83) 0.002
SaO2 [%] 0.98 (0.96–0.99) 0.026 1.00 (0.98–1.01) 0.96 1.02 (1.00–1.04) 0.024
Age > 75 1.28 (0.94–1.74) 0.110 0.73 (0.52–1.02) 0.07 1.02 (0.74–1.39) 0.90
Syncope 2.15 (1.23–3.74) 0.007 0.69 (0.36–1.32) 0.27 0.56 (0.29–1.08) 0.085
Concomitant DVT 1.26 (0.95–1.66) 0.09 0.95 (0.71–1.27) 0.72 0.81 (0.61–1.09) 0.17
30-day mortality 1.9 (1.2–3.1) 0.006 0.7 (0.4–1.2) 0.25 0.62 (0.3–1.0) 0.08
OR — odds ratio; CI — confidence interval; RVD — right ventricular dysfunction; SaO2 — oxygen saturation of arterial blood; DVT — deep 
venous thrombosis
Figure 2. Cumulative risk of death in the study popula-
tion according to localization of thrombus.
Table 3. In multivariable Cox’s regression analysis 
for 30-day all cause mortality in normotensive 
patients with pulmonary embolism.
Localization  
of thrombus
OR 95% CI P
Central 1.01 1.0–1.02 NS
RVD on echo 0.80 0.46–1.54 NS
Positive troponin 2.8 1.50–5.10 0.001
High risk sPESI 5.0 1.74–14.10 0.003
OR — odds ratio; CI — confidence interval; NS — non-significant; 
RVD — right ventricular dysfunction; sPESI — simplified pulmonary 
embolism index
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Kaplan-Meier analysis assessing the 30-day 
mortality rates with respect to the localization of 
thrombus did not establish any statistically signifi-
cant difference (Fig. 2). 
Discussion
Although the present study demonstrated that 
30-day mortality rate was increased in hemody-
namically stable PE patients with central thrombus 
diagnosed by MDCT, multivariate analysis did not 
show a significant impact of thrombus localization 
on 30-day mortality. Troponin levels however, 
were significantly increased and RVD determined 
by echocardiography was more common among 
patients with central thrombus. Another very 
important finding of this study was the similarity 
between the efficacies of LMWH and UFH in the 
treatment of patients with central thrombus. 
It is commonly known that risk stratification 
is essential to tailor the appropriate treatment 
modalities in PE patients. The localization of 
emboli as determined by MDCT angiography has 
been suggested to be useful for risk stratification 
in hemodynamically stable patients with acute PE 
[6, 7]. A recent meta-analysis including 5 studies 
and 2215 patients demonstrated an association 
between localization of thrombus in central arteries 
and 30-day mortality [8].
Data available in the literature concerning 
the prognosis of patients with central PE are 
controversial. Klok et al. [9] demonstrated cen-
tral thrombi in 28% of 674 PE patients, and they 
suggested that central localization of thrombus 
does not affect mortality within 90 days. In one 
previous study, no effect was detected of central 
thrombus on the rate of mortality in hemodynami-
cally stable patients with PE [10]. In another study, 
central thrombus was shown to be an independent 
predictor of all-cause death or clinical deterioration 
in hemodynamically stable patients (p = 0.047). 
Clinical deterioration was arterial hypotension 
requiring catecholamine infusion, endotracheal 
intubation, worsening symptoms and respiratory 
failure or recurrent PE [11]. In that study however, 
thrombus localization was central in the majority of 
cases (60%) and the reported p value was border-
line significant [12]. In the present study, thrombus 
was centrally localized in a relatively small number 
of patients (37%). 
In the present study, it was demonstrated 
that RVD determined by echocardiography was 
more common in patients with central thrombus. 
This is not necessarily a reason for a greater right 
ventricular afterload, as was also determined the 
peripheral microembolisms may have resulted in 
a major increase in pulmonary vascular resistance 
[13, 14]. Especially in patients with widespread 
thrombus, rapid hemodynamic collapse may be 
observed before adaptation in the right ventricle 
and syncope can be defined as an important clini-
cal finding of this condition. In this study, syncope 
was twice as common among patients with central 
thrombus. Similarly, Berghaus et al. [15] reported 
the presence of central thrombus as an independ-
ent risk factor for RVD on echocardiography. Con-
versely, one meta-analysis found that the mortality 
rate was increased by 1.8 fold in patients with RVD 
determined by CT [8].
Cardiac troponins are the most specific and 
sensitive markers of myocardial necrosis and 
myocardial cellular damage. Troponin increase was 
shown to be a marker of RVD and was associated 
with elevated early mortality rates in cases with 
acute PE [16, 17]. However, the relation between 
troponin levels and localization of the emboli has 
not been sufficiently investigated. In patients with 
non-massive central PE who were admitted to the 
emergency room, increased troponin I levels were 
shown to be useful in identifying those with high 
risk of developing hemodynamic instability, inde-
pendent of a clinically-based risk score [18]. In this 
study, cases with central thrombus had statistically 
Table 4. 30-day mortality according to different 
treatment regimens in central thrombus by  
univariable Cox’s analysis.
P OR 95% CI
Lower Upper
Unfractionated  
heparin
NS 1.482 0.720 3.048
Thrombolytic  
therapy
NS 0.203 0.027 1.530
Low molecular  
weight heparin
NS 1.054 0.523 2.127
Values are given in percent and 95% confidence interval (CI); OR — 
odds ratio; NS — non-significant
Table 5. The relationship between the central 
thrombosis and simplified pulmonary embolism 
index (sPESI).
sPESI (+) sPESI (–)
Central thrombus (+) 244 (41.3%) 75 (26.5%)
Central thrombus (–) 347 (58.7%) 208 (73.5%)
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significantly higher troponin levels and frequent 
signs of RVD on echocardiography, compared to 
cases with distal thrombus. It was also revealed 
that an elevated troponin level was an independent 
predictor of mortality. 
According to this research thus far, no study 
has demonstrated an association between central 
thrombus and sPESI. In the present study, pa-
tients with high risk sPESI more often had central 
thrombus. This may be explained by the presence 
of sPESI criteria such as tachycardia and desatura-
tion, which are more commonly observed among 
patients with central thrombus.
Studies investigating poor prognosis in pa-
tients with central thrombus reported limited data 
on the choice of anticoagulants. In cases where the 
presence of a central thrombus is considered to be 
a sign of RVD, it can be recommended to categorize 
these patients to submassive/intermediate risk 
groups. On the other hand, use of thrombolytic 
treatment in submassive PE is still controversial 
[19, 20]. However, UFH is preferred during the 
initial stage of massive PE and therefore, it can 
be concluded that UFH may be more effective in 
cases with central thrombus. The present study 
showed that there was no significant difference 
between UFH and LMWH in terms of efficacy. 
Since the study is not randomize controlled study 
(RCT), the view put forward herein is an assump-
tion. To prove this, RCT work is needed. Moreover, 
mortality rate did not change with thrombolytic 
treatment in hemodynamically stable cases with 
central thrombus. In a previous study, Hamel et al. 
[21] compared thrombolytics and heparin therapy 
in patients with submassive and demonstrated 
greater improvement on perfusion lung scans of 
the patients treated with thrombolytics compared 
to those treated with heparin. In that study how-
ever, the in-hospital mortality rate was 6.25% in the 
thrombolytic group and 0.0% in the heparin group 
[21]. On the other hand, a recent meta-analysis of 
7 studies including a total number of 594 patients 
reported that the cumulative effect of thrombolysis 
did not result in a statistically significant differ-
ence in mortality compared to intravenous heparin 
therapy [22].
Clinical findings of the present study can be 
summarized as follows: 1) No differences were 
observed with regard to mortality when UFH and 
LMWH treatments were compared; 2) Although 
the presence of central thrombus was not found 
to be an independent predictor of mortality, it can 
be concluded that ideally these patients should be 
treated in hospital settings since central throm-
bus is more commonly associated with RVD and 
elevated troponin levels. On the other hand, it has 
been previously suggested that distal embolism in 
hemodynamically stable patients can be treated in 
an outpatient setting [23].
Limitations of the study
This study has some limitations. Firstly, pul-
monary occlusion index or right ventricle/left 
ventricle ratios on CT were not calculated. In ad-
dition, when interpreting the results of the present 
study, one should consider that no autopsy was 
performed. Moreover, each study centre used 
different scans of multi-slice CTs. Nevertheless, 
it was believed to not have affected localization of 
the thrombus (central, lobar, distal). 
Conclusions
In conclusion, the present study demonstrated 
that 30-day mortality rate was higher in patients 
with central thrombus compared to the other pa-
tients. However, hemodynamically stable central 
thrombus was not found to be an independent 
predictor of mortality. 
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